1,904.50p
+0.77%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.
View GSK plc on TradingView ↗- Market value
- £76.31bn
- Last close × shares
- Volume
- 4.2m
- Shares, 9 Nov 2026
- Price to earnings
- 1196.3
- Dividend yield
- 0.04%
About GSK plc
Its shares trade on LSE under the ticker GSK.L. It has been listed since 22 May 1972. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of £32.67bn and net income of £5.72bn. At that date it held total assets of £61.12bn and shareholders' equity of £16.38bn.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex. The firm operates through two segments: Pharmaceuticals and Vaccines. The firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The firm makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The company has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Figures and description from our data supplier, not checked against the company's own report.
How it makes its money
Revenue, year to 31 Dec 2023
- Commercial Operations £30.33bn · 100.0%
Latest on GSK plc
Our reporting
- GSK plc rises 2.89% in Thursday's session
- GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
- UK's FTSE 100 muted as GSK, Unilever losses temper bank gains after budget
- GSK pipeline doubts, vaccine underperformance overshadow sales beat
- GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan
- Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
Next results
Due on 3 Feb 2027. Analysts expect earnings of 0.28 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is GSK plc's ticker?
GSK plc trades as GSK.L on LSE, under ISIN GB00BN7SWP63.
What was GSK plc's last closing price?
1,904.50p on 9 Nov 2026. The figure is in GBp and is never converted.
When does GSK plc next report results?
Results are expected on 3 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- Our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.